Phase I trial of pentosan polysulfate

Sandra M. Swain, Bernard Parker, Anton Wellstein, Marc E. Lippman, Caryn Steakley, Robert DeLap

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Pentosan polysulfate is a semisynthetic pentasaccharide heparinoid derived from beechwood shavings. A total of nineteen patients with various adult solid tumors were treated with three dose levels (15, 22.5, and 30 mg/m2/dose) of subcutaneous pentosan polysulfate every 6 hours. The dose limiting toxicities were thrombocytopenia and elevated transaminases at the dose of 30 mg/m2 every 6 hours. The recommended starting dose for phase II trials is 22.5 mg/m2 given every 6 hours. There was an increase in anticoagulant activity as measured by activated partial thromboplastin time (aPTT) at the dose of 22.5 mg/m2 every 6 hours in most patients. There were no objective responses and three patients had stable disease lasting 16, 19 and 76 weeks.

Original languageEnglish (US)
Pages (from-to)55-62
Number of pages8
JournalInvestigational New Drugs: An Interdisciplinary Journal for Clinicians and Scientists
Issue number1
StatePublished - Mar 1995


  • Adult solid tumors
  • Pentosan polysulfate
  • Phase I trial

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Phase I trial of pentosan polysulfate'. Together they form a unique fingerprint.

Cite this